These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 4424774)

  • 21. Antibody-induced killing in vivo of L1210/MTX-R cells quantitated in passively immunized mice with 131I-iododeoxyuridine-labeled cells and whole-body measurement of retained radioactivity.
    Carlson GA; Terres G
    J Immunol; 1976 Sep; 117(3):822-9. PubMed ID: 956654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunologic cross-reactivity of antigen(s) induced by drug treatment in two leukemic sublines.
    Nicolin A; Bini A; Di Padova F; Goldin A
    J Immunol; 1976 May; 116(5):1347-9. PubMed ID: 58028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
    Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
    Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergy between low-dose chemotherapy and immunotherapy in mouse L1210 leukemia.
    Relyveld EH; Bizzini B; Ophir R; Ben-Efraim S
    Cancer Treat Rep; 1987 Mar; 71(3):241-6. PubMed ID: 3102055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 26. Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia.
    Bortin MM; Rimm AA; Saltzstein EC
    Science; 1973 Feb; 179(4075):811-3. PubMed ID: 4405359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunostimulatory factors specifically associated with a spontaneously regressing tumor subline of the murine leukemia L1210.
    Koo PH
    J Immunol; 1981 Jul; 127(1):373-9. PubMed ID: 7016996
    [No Abstract]   [Full Text] [Related]  

  • 28. Central inhibition of cellular immunity to leukemia L1210 by isoantibody.
    Mitchell MS
    Cancer Res; 1972 Apr; 32(4):825-31. PubMed ID: 4622583
    [No Abstract]   [Full Text] [Related]  

  • 29. Improved host defense against L1210 leukemia by deprivation of dietary phenylalanine.
    Pine MJ
    Nutr Cancer; 1981; 3(2):94-102. PubMed ID: 7346795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Active immunotherapy in spontaneous leukemia of AkR mice.
    Mathé G; Halle-Pannenko O; Bourut C
    Exp Hematol; 1973; 1(2):110-4. PubMed ID: 4609352
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
    Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
    Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC
    Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged survival in long-passage AKR leukemia using chemotherapy, radiotherapy, and adoptive immunotherapy.
    Bortin MM; Rimm AA; Rodey GE; Giller R; Saltzstein EC
    Cancer Res; 1974 Aug; 34(8):1851-6. PubMed ID: 4152270
    [No Abstract]   [Full Text] [Related]  

  • 34. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
    Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
    J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Inhibition of the effect of immunocytotherapy in leukemia in mice under stress and the possibilities of its withdrawal].
    Sukhikh GT
    Biull Eksp Biol Med; 1984 Dec; 98(12):694-6. PubMed ID: 6542442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
    Kawalec M; Skórski T; Kawiak J
    Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of adoptive transfer and Winn assay procedures in the further analysis of antiviral acquired immunity in mice protected against Friend leukemia virus-induced disease by passive serum therapy.
    Genovesi EV; Pettey CL; Collins JJ
    Cancer Res; 1984 Apr; 44(4):1489-98. PubMed ID: 6608407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the biochemical pharmacology of selected alkylating agents.
    Wheeler GP
    Transplant Proc; 1973 Sep; 5(3):1167-70. PubMed ID: 4738047
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunomodulation of host resistance by tumor variants.
    Fuji H
    Transplant Proc; 1984 Apr; 16(2):460-2. PubMed ID: 6609454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.